17734-23-5

Upstream product

• 10472-97-6 8-phenyloctan-1-ol 
• 1421864-49-4 phenyloctyl methanesulfonate 
• 17734-25-7 7-phenyl-1-cyanoheptane 
• 78573-85-0 1-bromo-7-phenyl-heptane 
• 3208-25-1 7-phenylheptan-1-ol 

Downstream Products

• 1415221-95-2 benzyl N--Fmoc--(2S)--2--amino--4--oxo--4--((8--phenyloctyl)amino)butanoate 
• 1415221-85-0 N--Fmoc--(2S)-2--amino--4--oxo--4--((8--phenyloctyl)amino)butanoic acid 
• 251478-09-8 2,6-Diiodo-4-(8-phenyloctylcarbamoyl)phenol 
• 251477-39-1 N-(8-phenyl-octyl)-3,5-bis(m-trifluoromethylphenyl)-4-(2-hydroxyethoxy)-benzamide 
• 251478-57-6 N-(8-phenyloctyl)-3-(4-methoxyphenyl)-5-(3-trifluoromethylphenyl)-4-(2-hydroxyethoxy)benzamide 
• 251477-34-6 N-(8-phenyl-octyl)-3,5-bis-(m-chlorophenyl)-4-(2-hydroxyethoxy)-benzamide 

Relevant academic research and scientific papers

Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1)

We report herein that incorporating long-chain alkylphenyl-containing non-proteinogenic amino acids in place of His at the pT-2 position of the parent polo-like kinase 1 (Plk1) polo box domain (PBD)-binding pentapeptide, PLHSpT (1a) increases affinity. Fo

Cyanoguanidines as cell proliferation inhibitors

The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, the attachment to the pyridine being in the 3- or 4-position, in which formula R1 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl nitro, amino, cyano, carboxy, or alkyl, alkoxy, or alkoxycarbonyl, the C-content of which can be from 1 to 4; X stands for a straight or branched C9-C20 carbon chain, saturated or unsaturated or Q—Ar—R; in which formula Ar stands for phenyl, Q stands for a C5-C20 divalent hydrocarbon radical which can be straight, branched, saturated or unsaturated and R stands for hydrogen or for one or more substituents which can be the same or different and are selected from the group consisting of: hydroxy, amino, halogen, trifluoromethyl, cyano, nitro, carboxy, carbamoyl, or alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 4; and pharmaceutically acceptable, non-toxic salts and N-oxides thereof. The present compounds are of value in the human and veterinary practice.